Anteris Technologies Global’s (AVR) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Anteris Technologies Global (NASDAQ:AVR) in a research report report published on Wednesday,Benzinga reports. The firm currently has a $15.00 price target on the stock.

A number of other research firms have also recently commented on AVR. Weiss Ratings restated a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Wednesday, August 26th. Barclays upgraded shares of Anteris Technologies Global to a “hold” rating in a report on Wednesday, October 7th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $14.00.

Anteris Technologies Global Stock Performance

Shares of AVR stock opened at $6.05 on Wednesday. The company has a market cap of $589.63 million, a P/E ratio of -3.10 and a beta of 1.87. The stock has a 50 day simple moving average of $8.18 and a two-hundred day simple moving average of $8.05. Anteris Technologies Global has a fifty-two week low of $3.30 and a fifty-two week high of $11.06.

Anteris Technologies Global (NASDAQ:AVR) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.09). Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. The business had revenue of $1.01 million during the quarter, compared to analyst estimates of $1.50 million. During the same period last year, the firm posted ($0.58) earnings per share. On average, research analysts predict that Anteris Technologies Global will post -1.21 earnings per share for the current year.

Insider Buying and Selling

In other news, major shareholder L1 Capital Pty Ltd acquired 272,695 shares of the firm’s stock in a transaction dated Tuesday, October 6th. The stock was purchased at an average price of $7.18 per share, for a total transaction of $1,957,950.10. Following the completion of the acquisition, the insider directly owned 6,358,271 shares in the company, valued at $45,652,385.78. The trade was a 4.48% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last ninety days, insiders purchased 1,554,730 shares of company stock valued at $11,694,513 and sold 3,008,459 shares valued at $25,243,576. Company insiders own 4.50% of the company’s stock.

Hedge Funds Weigh In On Anteris Technologies Global

A number of large investors have recently modified their holdings of AVR. Forum Financial Management LP raised its holdings in Anteris Technologies Global by 266.1% during the third quarter. Forum Financial Management LP now owns 40,008 shares of the company’s stock worth $311,000 after buying an additional 29,081 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Anteris Technologies Global by 26,789.3% in the third quarter. Farther Finance Advisors LLC now owns 15,058 shares of the company’s stock valued at $117,000 after buying an additional 15,002 shares in the last quarter. Nantahala Capital Management LLC acquired a new position in shares of Anteris Technologies Global during the second quarter valued at about $33,325,850. One68 Global Capital LLC acquired a new position in shares of Anteris Technologies Global during the second quarter valued at about $128,000. Finally, Bank of America Corp DE acquired a new position in shares of Anteris Technologies Global during the second quarter valued at about $1,907,000.

About Anteris Technologies Global

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.